NCT00117299View on ClinicalTrials.gov

PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

January 31, 2009

Conditions
Sarcoma
Interventions
DRUG

PTK787/ZK222584

PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally

Trial Locations (1)

FIN-00029

Helsinki University Central Hospital, Helsinki

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Helsinki

OTHER

NCT00117299 - PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib | Biotech Hunter | Biotech Hunter